Product was Cryoport’s largest product and service line in fiscal 2025, bringing in $159.36M of $352.35M (45%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Product | $206.80M | $178.34M | $159.36M | |||||
| Biologistics Solutions | $249.60M | $131.81M | $156.27M | |||||
| Service | — | $158.99M | — | |||||
| Biopharmaceutical | — | — | — | |||||
| Biopharma/Pharma | — | — | — | |||||
| Biostorage/Bioservices | $18.16M | — | $36.72M | |||||
| Animal Health | — | — | — | |||||
| Reproductive Medicine | — | — | — | |||||
| Total | $474.55M | $469.13M | $352.35M |
Cryoport brought in $352.35M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. Cryoport regrouped these lines after fiscal 2023, so the total does not compare directly with that year's $469.13M. Product was the largest at $159.36M (45.2%), ahead of Biologistics Solutions at $156.27M (44.4%) and Biostorage/Bioservices at $36.72M (10.4%).
Compared with fiscal 2023, the previous year with figures, Biologistics Solutions grew 18.6% to $156.27M, while Product fell 10.6% to $159.36M. From fiscal 2022 to 2025, combined revenue from these lines fell from $474.55M to $352.35M, a compound annual decline of 9.4%. Product's share of the total rose from 43.6% to 45.2%.
Cryoport stopped reporting Service as a separate line after fiscal 2023, when it brought in $158.99M.
Americas was Cryoport’s largest region in fiscal 2025, bringing in $262.52M of $352.35M (75%).
| Geography | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Americas | $256.42M | $262.52M | |||||
| Emea | $133.83M | $50.27M | |||||
| Europe, The Middle East & Africa (Emea) | — | — | |||||
| Asia Pacific | $84.31M | $39.57M | |||||
| Asia Pacific (Apac) | — | — | |||||
| Total | $474.55M | $352.35M |
Cryoport brought in $352.35M from its three regions in fiscal 2025, the year ended December 31, 2025. That was down 25.8% from $474.55M in fiscal 2022, the previous year with figures. Americas was the largest at $262.52M (74.5%), ahead of Emea at $50.27M (14.3%) and Asia Pacific at $39.57M (11.2%).
Compared with fiscal 2022, the previous year with figures, Americas grew fastest, up 2.4% to $262.52M, while Emea fell the most, down 62.4% to $50.27M. From fiscal 2022 to 2025, combined revenue from these regions fell from $474.55M to $352.35M, a compound annual decline of 9.4%. Americas' share of the total rose from 54.0% to 74.5%.
Cryoport (CYRX) reports its revenue by product and service and by geography. In fiscal 2025, Product was its largest product and service line, bringing in $159.36M (45.2% of the total), followed by Biologistics Solutions at $156.27M (44.4%).
Product was Cryoport's largest product and service line in fiscal 2025, bringing in $159.36M, or 45.2% of the $352.35M total across its three product and service lines.
Americas was Cryoport's largest region in fiscal 2025, bringing in $262.52M, or 74.5% of the $352.35M total across its three regions.
Every figure comes from Cryoport's annual financial filings, as reported. Each line keeps the name Cryoport gives it, and years follow its fiscal calendar.
Cryoport's revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.